ID   ST88-14
AC   CVCL_8916
SY   ST88.14; ST 88-14; ST-8814; ST8814; 88-14; NF188-14
DR   EFO; EFO_0006295
DR   cancercelllines; CVCL_8916
DR   Cosmic; 1132063
DR   Cosmic; 1644550
DR   Cosmic; 1801814
DR   Cosmic; 2307729
DR   GEO; GSM1676331
DR   GEO; GSM1701663
DR   Wikidata; Q54955754
RX   PubMed=1568246;
RX   PubMed=1906341;
RX   PubMed=7627966;
RX   PubMed=9766530;
RX   PubMed=10791998;
RX   PubMed=16239399;
RX   PubMed=16510576;
RX   PubMed=18650488;
RX   PubMed=21084276;
RX   PubMed=22346343;
RX   PubMed=23437333;
RX   PubMed=24726063;
RX   PubMed=26351324;
RX   PubMed=28469964;
RX   PubMed=28556483;
RX   PubMed=32076030;
RX   PubMed=32642732;
CC   Doubling time: ~24 hours (PubMed=21084276).
CC   Sequence variation: Mutation; HGNC; 7765; NF1; Simple; p.Arg304Ter (c.910C>T); ClinVar=VCV000187722; Zygosity=Unspecified (PubMed=32642732).
ST   Source(s): PubMed=28556483; PubMed=32076030
ST   Amelogenin: X,Y
ST   CSF1PO: 9,12
ST   D13S317: 12
ST   D16S539: 13
ST   D18S51: 12
ST   D19S433: 13,14
ST   D21S11: 29,32.2
ST   D2S1338: 17,23
ST   D3S1358: 15 (PubMed=28556483)
ST   D3S1358: 15,18 (PubMed=32076030)
ST   D5S818: 12,13
ST   D7S820: 8
ST   D8S1179: 14
ST   FGA: 21
ST   Penta D: 9,13
ST   Penta E: 16
ST   TH01: 9
ST   TPOX: 11,12
ST   vWA: 16
DI   NCIt; C3798; Malignant peripheral nerve sheath tumor
DI   NCIt; C3273; Neurofibromatosis type 1
DI   ORDO; Orphanet_3148; Malignant peripheral nerve sheath tumor
DI   ORDO; Orphanet_636; Neurofibromatosis type 1
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
CA   Cancer cell line
DT   Created: 06-06-12; Last updated: 02-05-24; Version: 22
//
RX   PubMed=1568246; DOI=10.1016/0092-8674(92)90407-4;
RA   DeClue J.E., Papageorge A.G., Fletcher J.A., Diehl S.R., Ratner N.,
RA   Vass W.C., Lowy D.R.;
RT   "Abnormal regulation of mammalian p21ras contributes to malignant
RT   tumor growth in von Recklinghausen (type 1) neurofibromatosis.";
RL   Cell 69:265-273(1992).
//
RX   PubMed=1906341; DOI=10.1002/gcc.2870030111;
RA   Glover T.W., Stein C.K., Legius E., Andersen L.B., Brereton A.,
RA   Johnson S.;
RT   "Molecular and cytogenetic analysis of tumors in von Recklinghausen
RT   neurofibromatosis.";
RL   Genes Chromosomes Cancer 3:62-70(1991).
//
RX   PubMed=7627966;
RA   Yan N., Ricca C.S., Fletcher J.A., Glover T.W., Seizinger B.R.,
RA   Manne V.;
RT   "Farnesyltransferase inhibitors block the neurofibromatosis type I
RT   (NF1) malignant phenotype.";
RL   Cancer Res. 55:3569-3575(1995).
//
RX   PubMed=9766530; DOI=10.1002/(SICI)1097-4652(199811)177:2<334::AID-JCP15>3.0.CO;2-9;
RA   Badache A., de Vries G.H.;
RT   "Neurofibrosarcoma-derived Schwann cells overexpress platelet-derived
RT   growth factor (PDGF) receptors and are induced to proliferate by PDGF
RT   BB.";
RL   J. Cell. Physiol. 177:334-342(1998).
//
RX   PubMed=10791998; DOI=10.1172/JCI7610;
RA   DeClue J.E., Heffelfinger S.C., Benvenuto G., Ling B., Li S.-W., Rui W.,
RA   Vass W.C., Viskochil D., Ratner N.;
RT   "Epidermal growth factor receptor expression in neurofibromatosis type
RT   1-related tumors and NF1 animal models.";
RL   J. Clin. Invest. 105:1233-1241(2000).
//
RX   PubMed=16239399; DOI=10.1124/jpet.105.091454;
RA   Mattingly R.R., Kraniak J.M., Dilworth J.T., Mathieu P., Bealmear B.,
RA   Nowak J.E., Benjamins J.A., Tainsky M.A., Reiners J.J. Jr.;
RT   "The mitogen-activated protein kinase/extracellular signal-regulated
RT   kinase kinase inhibitor PD184352 (CI-1040) selectively induces
RT   apoptosis in malignant schwannoma cell lines.";
RL   J. Pharmacol. Exp. Ther. 316:456-465(2006).
//
RX   PubMed=16510576; DOI=10.1158/0008-5472.CAN-05-3330;
RA   Miller S.J., Rangwala F., Williams J., Ackerman P., Kong S.,
RA   Jegga A.G., Kaiser S., Aronow B.J., Frahm S., Kluwe L., Mautner V.-F.,
RA   Upadhyaya M., Muir D.F. IV, Wallace M.R., Hagen J., Quelle D.E.,
RA   Watson M.A., Perry A., Gutmann D.H., Ratner N.;
RT   "Large-scale molecular comparison of human Schwann cells to malignant
RT   peripheral nerve sheath tumor cell lines and tissues.";
RL   Cancer Res. 66:2584-2591(2006).
//
RX   PubMed=18650488; DOI=10.1215/15228517-2008-053;
RA   Holtkamp N., Malzer E., Zietsch J., Okuducu A.F., Mucha J., Mawrin C.,
RA   Mautner V.-F., Schildhaus H.-U., von Deimling A.;
RT   "EGFR and erbB2 in malignant peripheral nerve sheath tumors and
RT   implications for targeted therapy.";
RL   Neuro-oncol. 10:946-957(2008).
//
RX   PubMed=21084276; DOI=10.1158/0008-5472.CAN-10-2799;
RA   Lopez G., Torres K.E., Liu J.J.-H., Hernandez B., Young E.D., Belousov R.,
RA   Bolshakov S.V., Lazar A.J.F., Slopis J.M., McCutcheon I.E., McConkey D.J.,
RA   Lev D.C.;
RT   "Autophagic survival in resistance to histone deacetylase inhibitors:
RT   novel strategies to treat malignant peripheral nerve sheath tumors.";
RL   Cancer Res. 71:185-196(2011).
//
RX   PubMed=22346343; DOI=10.4137/TOG.S8830;
RA   Sun D., Tainsky M.A., Haddad R.;
RT   "Oncogene mutation survey in MPNST cell lines enhances the dominant
RT   role of hyperactive Ras in NF1 associated pro-survival and
RT   malignancy.";
RL   Transl. Oncogenomics 5:1-7(2012).
//
RX   PubMed=23437333; DOI=10.1371/journal.pone.0057152;
RA   Reuss D.E., Mucha J., Hagenlocher C., Ehemann V., Kluwe L.,
RA   Mautner V.-F., von Deimling A.;
RT   "Sensitivity of malignant peripheral nerve sheath tumor cells to TRAIL
RT   is augmented by loss of NF1 through modulation of MYC/MAD and is
RT   potentiated by curcumin through induction of ROS.";
RL   PLoS ONE 8:E57152-E57152(2013).
//
RX   PubMed=24726063; DOI=10.1186/1756-9966-33-33;
RA   Koelsche C., Renner M., Hartmann W., Brandt R., Lehner B.,
RA   Waldburger N., Alldinger I., Schmitt T., Egerer G., Penzel R.,
RA   Wardelmann E., Schirmacher P., von Deimling A., Mechtersheimer G.;
RT   "TERT promoter hotspot mutations are recurrent in myxoid liposarcomas
RT   but rare in other soft tissue sarcoma entities.";
RL   J. Exp. Clin. Cancer Res. 33:33.1-33.8(2014).
//
RX   PubMed=26351324; DOI=10.1158/1535-7163.MCT-15-0074;
RA   Teicher B.A., Polley E.C., Kunkel M., Evans D., Silvers T.E.,
RA   Delosh R.M., Laudeman J., Ogle C., Reinhart R., Selby M., Connelly J.,
RA   Harris E., Monks A., Morris J.;
RT   "Sarcoma cell line screen of oncology drugs and investigational agents
RT   identifies patterns associated with gene and microRNA expression.";
RL   Mol. Cancer Ther. 14:2452-2462(2015).
//
RX   PubMed=28469964;
RA   Guo J.-M., Grovola M.R., Xie H., Coggins G.E., Duggan P., Hasan R.,
RA   Huang J.-L., Lin D.W., Song C., Witek G.M., Berritt S., Schultz D.C.,
RA   Field J.;
RT   "Comprehensive pharmacological profiling of neurofibromatosis cell
RT   lines.";
RL   Am. J. Cancer Res. 7:923-934(2017).
//
RX   PubMed=28556483; DOI=10.1002/1878-0261.12086;
RA   Kolberg M., Bruun J., Murumagi A., Mpindi J.P., Bergsland C.H.,
RA   Holand M., Eilertsen I.A., Danielsen S.A., Kallioniemi O.-P.,
RA   Lothe R.A.;
RT   "Drug sensitivity and resistance testing identifies PLK1 inhibitors
RT   and gemcitabine as potent drugs for malignant peripheral nerve sheath
RT   tumors.";
RL   Mol. Oncol. 11:1156-1171(2017).
//
RX   PubMed=32076030; DOI=10.1038/s41598-020-59789-4;
RA   Amirnasr A., Verdijk R.M., van Kuijk P.F., Kartal P., Vriends A.L.M.,
RA   French P.J., van Royen M.E., Taal W., Sleijfer S., Wiemer E.A.C.;
RT   "Deregulated microRNAs in neurofibromatosis type 1 derived malignant
RT   peripheral nerve sheath tumors.";
RL   Sci. Rep. 10:2927-2927(2020).
//
RX   PubMed=32642732; DOI=10.1093/noajnl/vdz049;
RA   Pemov A., Li H., Presley W., Wallace M.R., Miller D.T.;
RT   "Genetics of human malignant peripheral nerve sheath tumors.";
RL   Neurooncol. Adv. 2:I50-I61(2020).
//